Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1995893

Cc1cc2c(c3cc[nH]c13)CN(C)CCO2.O=C(O)C(F)(F)F

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CREBBP Q92793 2/20 0.35
CFB P00751 7/20 0.34
P2RX7 Q99572 3/20 0.34
HDAC1 Q13547 2/20 0.33
HDAC6 Q9UBN7 2/20 0.33
HDAC8 Q9BY41 1/20 0.33
RIPK1 Q13546 2/20 0.33
GOT1 P17174 1/20 0.32
AR P10275 1/20 0.32
PKM P14618 1/20 0.32
NLRP3 Q96P20 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL1995099 0.73 HTR6 (0.39) PKM
SCHEMBL1995896 0.72 CFB (0.34) CFBP2RX7
SCHEMBL1996281 0.68 CREBBP (0.40) CREBBP
Trifluoroacetic Acid SCHEMBL17957543 0.66 HDAC6 (0.43) HDAC1HDAC6HDAC8RIPK1
Trifluoroacetic Acid SCHEMBL1996217 0.66 HTR6 (0.42) HDAC1HDAC6HDAC8PKM
Trifluoroacetic Acid SCHEMBL1997458 0.65 HTR6 (0.47) HDAC1HDAC6HDAC8PKM
Trifluoroacetic Acid SCHEMBL1997490 0.64 HTR6 (0.41) PKM
SCHEMBL1997771 0.62 HTR6 (0.44) PKM
SCHEMBL15797535 0.60 P2RX7 (0.58) CFBP2RX7
SCHEMBL28609257 0.59 LMNA (0.34) PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960374-B2 e.g. 2,5-methylene-9-(phenylsulfonyl)-1,2,3,4,5,9-hexahydro[1,5]oxazocino[3,2-e]indole; serotonin receptors antagonist or partial agonist; metabolic diseases, e.g. obesity, insulin resisitance, type 2 diabetes, eating disorders; antidepressant, anxiolytic agent; cosmetics PROXIMAGEN LIMITED (GB) 2011-06-14 US disclosed
EP-2091953-A1 8-SULFONYL-L, 3, 4, 8-TETRAHYDR0-2H- [1, 4]OXAZEPINO [6, 7-E]INDOLE DERIVATIVES AND THEIR USE AS 5-HT6 RECEPTOR LIGANDS BIOVITRUM AB (publ) (SE) 2009-08-26 EP disclosed
US-20080176829-A1 Compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2008-07-24 US disclosed
WO-2008054288-A1 8-SULFONYL-L, 3, 4, 8-TETRAHYDR0-2H- [1, 4] OXAZEPINO [6, 7-E] INDOLE DERIVATIVES AND THEIR USE AS 5-HT6 RECEPTOR LIGANDS BIOVITRUM AB (PUBL) (SE) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176829-A1 Compounds HTR6, HTR1B, HTR1A CREBBP 2723/4885CFB 1855/4885P2RX7 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.